Thousands of people with HIV in the UK could soon receive a revolutionary long-acting injection in the latest bid to combat the HIV/AIDS crisis. We have seen a rapid spike in interest and research surrounding the virus—including clinical trials into the condition by companies like Moderna, one of the first biotechs to develop a widely used COVID-19 vaccine—since the pandemic started. People living with HIV will soon be rid of the burden that comes with ingesting daily pills, thanks to this new alternative remedy. The first long-acting injectable will certainly help us reach the goal of eliminating HIV transmission in England by 2030.

HIV virus, which attacks the immune system, still remains incurable. Regardless, charities and organisations have welcomed the groundbreaking news with open arms—praising the move approved by the NHS. The National AIDS Trust estimates that about 105,000 people are living with HIV in Britain, with 98 per cent of diagnosed people currently on the treatment. This injectable could help over 13,000 eligible individuals who are currently residing in England alone. Previously, the only long-term treatment available to them was antiretroviral drugs. These drugs work by keeping the viral load—the number of virus particles in the blood—so low that it is “durably undetectable,” meaning it remains incognito for at least six months after a person’s first undetectable test result. Research has additionally shown that people who have HIV and are treated with these antiretroviral drugs do not sexually transmit the virus to other people.

Garry Brough, who previously co-founded the Bloomsbury Patients Network for people with HIV back in 1999 and now works at Positively UK, commented on the progress yet to be made in terms of the virus. “We still have a long way to go in educating around HIV, but today’s announcement demonstrates how far we’ve come since the 1980s epidemic,” Brough said, outlining how the latest innovation is a huge step in the right direction.

“Having to take tablets every day can be physically, emotionally and socially burdensome for some people. This decision reflects the rightful need for people living with HIV to have the freedom to manage their HIV in a way that works best for them, helping them to live their life to the full,” he continued.

A non-pill treatment plan will work well for those who face issues with multi-tablet regimens. This will also help to cut down how much the virus and treatment affect their daily life—given the fact that they are only required to take a shot every two months instead of the pills every day. Thereby, reducing the number of treatment days people are typically subjected to from 365 to just six per year.

The National Institute for Health and Care Excellence (NICE)—a public body of the Department of Health in England that publishes guidelines on various conditions and treatments—said that two types of drugs will be recommended to eligible adults after trials have successfully proved they work just as levels through the daily antiretroviral medicines. The long-acting injectable is a two-drug regime of cabotegravir (also known as vocabria) made by ViiV Healthcare—a joint venture pharmaceutical company for HIV infection between Pfizer and GlaxoSmithKline—with rilpivirine (also called Rekambys), made by Janssen. After an initial phasing-in period, cabotegravir and rilpivirine will be administered as two separate injections every two months. The former is also being studied as an investigational drug to prevent HIV infection at the moment, according to Clinical Info

This is the first recommendation NICE has made about the use of HIV treatments, since they came under its remit two years ago. While publishing the draft guidance recommending the injectable treatment, the institute has also stated that the clinical trial proved cabotegravir with rilpivirine to be as effective as oral antiretrovirals at maintaining a low viral load. The Scottish Medicines Consortium has also approved the use of cabotegravir injections for adults living with HIV in Scotland.

According to experts, switching out the task of taking medications every single day may lessen the emotional toll of living with HIV and improve the rate of people sticking to their treatment regime. Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, said: “Despite scientific advances, HIV is still incurable but the virus can be controlled by modern treatment.”

For some people, however, undergoing multi-tablet regimens on a daily basis can be difficult because of drug-related side effects, toxicity and other psychosocial issues—such as stigma or changes in lifestyle. “The committee heard that stigma remains an issue for people living with HIV and can have a negative impact on people’s health and relationships,” Boysen continued.

Many others have also weighed in, hailing the treatment as a “huge step forward.”  Debbie Laycock, head of policy at Terrence Higgins Trust, told The Guardian: “It’s incredible news for people living with HIV in England and Wales that they will be able to access the first long-acting injectable treatment on the NHS as an additional treatment option. Pill fatigue is also an issue for some people living with HIV who struggle with the idea of taking antiretroviral drugs every day.”

This news is undoubtedly a successful feat in the field of medicine and the quest to curing HIV in the future. “We’re pleased, therefore, to be able to recommend cabotegravir with rilpivirine as a valuable treatment option for people who already have good levels of adherence to daily tablets but who might prefer an injectable regimen with less frequent dosing,” Boysen concluded.